Impax Laboratories (IPXL) Misses Q2 EPS by 1c

Impax Laboratories (NASDAQ: IPXL) reported Q2 EPS of $0.34, $0.01 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $214.2 million versus the consensus estimate of $199.93 million.

For earnings history and earnings-related data on Impax Laboratories (IPXL) click here.

You May Also Be Interested In

• Benchmark on Take-Two's (TTWO) GTV 6 Release: 'we anticipate that the game will not be released within the fiscal year and expect it to launch in fiscal 2026 instead'
• American Express (AXP) down despite beating Q1 estimates on top and bottom lines
• Procter & Gamble (PG) Tops Q3 EPS by 11c, Revenues Miss